Trial Profile
Phase IV clinical trial of CEDARCURE(R)SLIT-tablet and MITICURE(R)SLIT-tablet. - Evaluation of safety in patients with both Japanese cedar pollinosis and HDM-induced allergic rhinitis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Dec 2021
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy-ALK Abello (Primary) ; Japanese cedar pollen allergy immunotherapy ALK Abello/Torii Pharmaceutical (Primary)
- Indications Allergic rhinitis; Seasonal allergic rhinitis
- Focus Adverse reactions
- Sponsors Torii Pharmaceutical
- 16 Mar 2020 Results of a subgroup analysis examining the safety across subgroups of children, adolescents, and adults were published at the 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 01 Jul 2019 Status changed from active, no longer recruiting to completed.
- 28 Aug 2018 Status changed from recruiting to active, no longer recruiting.